Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Connie Williams

Nurse Practitioner, Acute Care Jackson, MS Nurse Practitioner

NPI 1750735452 CMS profile 11171529

1860 Chadwick Dr, Suite 256, Jackson, MS 39204

Open in the dashboard

General payments

$5,776

285 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Connie Williams of Jackson, MS is reported in the CMS Open Payments database as having received $5,776 across 285 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Nurse Practitioner, Acute Care profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $864 36
2024 General $714 37
2023 General $766 47
2022 General $1,223 63
2021 General $2,209 102

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Connie Williams
  • Nurse Practitioner, Acute Care median
  • Middle half of Nurse Practitioner, Acute Care
  • National median

In program year 2025, general payments to Connie Williams were reported at $864. Among 11,827 Nurse Practitioner, Acute Care profiles paid that year, the median was $152 and the middle half received between $48 and $458.

Show as a table
Year Connie Williams Nurse Practitioner, Acute Care median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $2,209 $123 $38–$327 $132
2022 $1,223 $130 $44–$369 $149
2023 $766 $144 $49–$410 $160
2024 $714 $146 $48–$433 $164
2025 $864 $152 $48–$458 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Abbott Laboratories $1,487 69 payments
  2. Medtronic, Inc. $604 24 payments
  3. Novartis Pharmaceuticals Corporation $532 30 payments
  4. Merck Sharp & Dohme Corporation $457 22 payments
  5. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $288 26 payments
  6. Janssen Pharmaceuticals, Inc $281 18 payments
  7. Bayer HealthCare Pharmaceuticals Inc. $272 14 payments
  8. Bard Peripheral Vascular, Inc. $258 8 payments
  9. Inari Medical, Inc. $186 2 payments
  10. Pfizer Inc. $166 11 payments
  11. Other $1,245 61 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $5,776 285 payments
Products named General payments · program years 2021–2025
  1. VERQUVO Cardiovascular $543 27 payments
  2. LifeVest $288 26 payments
  3. XARELTO $281 18 payments
  4. FLOWTRIEVER CATHETER, S $275 3 payments
  5. GALLANT $240 7 payments
  6. ENTRESTO Cardiovascular $238 15 payments
  7. Verquvo Cardio-pulmonary $219 11 payments
  8. SYMPLICITY G3 $218 9 payments
  9. Supera peripheral stent system $182 4 payments
  10. ENTRESTO Cardiology/Vascular Diseases $177 8 payments
  11. Other $3,984 196 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 29 drugs

Part D claims

1,397

Median for Nurse Practitioner: 389

Drug cost

$261,267

Median for Nurse Practitioner: $21,885

Branded share of claims

35.4%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 161 $122,491
Entresto Sacubitril/Valsartan Brand 53 $51,351
Brilinta Ticagrelor Brand 41 $25,228
Farxiga Dapagliflozin Propanediol Brand 29 $22,977
Xarelto Rivaroxaban Brand 26 $19,898
Jardiance Empagliflozin Brand 12 $6,764
Isosorbide Dinit-Hydralazine Isosorbide Dinit/Hydralazine Brand 18 $3,195
Atorvastatin Calcium Generic 107 $1,095
Metoprolol Succinate Generic 119 $1,085
Felodipine Er Felodipine Brand 25 $748

The 10 drugs with the highest cost, of 29 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$20,023

Medicare's payments for the services billed

Medicare patients

198

Average age 74

Services billed

392

124 women, 74 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 46%
Ischemic heart disease 35%
Diabetes 33%
Atrial fibrillation 22%
Depression 22%
Chronic kidney disease 21%
Heart failure 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 9 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
VERQUVO
  • Merck Sharp & Dohme Corporation $133
$133 — —
LEQVIO
  • Novartis Pharmaceuticals Corporation $48
$48 — —
ENTRESTO
  • Novartis Pharmaceuticals Corporation $48
$48 53 —
Repatha
  • Amgen Inc. $46
$46 — —
FARXIGA
  • AstraZeneca Pharmaceuticals LP $32
$32 29 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 9 in the dashboard with a free account

Records

285 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Acute Care in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record